Payment overview · 2025
General Payments
$836.13
42 reported records · 16 companies
Healthcare provider profile · identity verified
Vicki Nigam, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MILWAUKEE, WI · NPI 1730679804
Verified facts
What the public records show
CMS Open Payments records show Vicki Nigam, NP received $836.13 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.51 | 19.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.95 | 12.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.20 | 11.4% | 5 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $59.03 | 7.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.68 | 6.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.88 | 6.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.92 | 5.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.65 | 5.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.60 | 5.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $38.11 | 4.6% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $27.73 | 3.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.82 | 3.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.17 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.80 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.47 | 2.5% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $19.61 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $836.13 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $150.51 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $97.11 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $79.00 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $79.00 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $79.00 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $68.92 | 3 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $59.03 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $50.88 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.65 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $42.32 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.03 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $27.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 21 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
113 | 57 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
53 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 619 | 236 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 163 |
| Metformin Hcl | Metformin Hcl | 333 | 123 |
| Gabapentin | Gabapentin | 281 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 72 |
| Lisinopril | Lisinopril | 229 | 75 |
| Omeprazole | Omeprazole | 218 | 104 |
| Losartan Potassium | Losartan Potassium | 191 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 79 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 172 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 171 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 141 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 60 |
| Allopurinol | Allopurinol | 139 | 51 |
| Linzess | Linaclotide | 113 | 57 |
| Glimepiride | Glimepiride | 110 | 44 |
| Cromolyn Sodium | Cromolyn Sodium | 108 | 64 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 108 | 61 |
| Farxiga | Dapagliflozin Propanediol | 96 | 39 |
| Ibuprofen | Ibuprofen | 95 | 59 |
| Meclizine Hcl | Meclizine Hcl | 89 | 46 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 31 |
| Prednisone | Prednisone | 88 | 67 |
| Trulicity | Dulaglutide | 88 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 40 |
| Carvedilol | Carvedilol | 79 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 28 |
| Furosemide | Furosemide | 77 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 27 |
| Simvastatin | Simvastatin | 67 | 30 |
| Clobetasol Propionate | Clobetasol Propionate | 63 | 25 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 63 | 24 |
| Alendronate Sodium | Alendronate Sodium | 61 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 61 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 19 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 53 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 51 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 40 |
| Sertraline Hcl | Sertraline Hcl | 52 | 24 |
| Potassium Chloride | Potassium Chloride | 51 | 21 |
| Hydrocortisone | Hydrocortisone | 50 | 28 |
| Ketoconazole | Ketoconazole | 50 | 21 |
| Mirtazapine | Mirtazapine | 50 | 20 |
| Azithromycin | Azithromycin | 46 | 40 |
| Amoxicillin | Amoxicillin | 44 | 39 |
| Nifedipine Er | Nifedipine | 43 | 20 |
| Fluconazole | Fluconazole | 40 | 16 |
| Metformin Hcl Er | Metformin Hcl | 40 | 18 |
| Montelukast Sodium | Montelukast Sodium | 40 | 14 |
| Ondansetron Odt | Ondansetron | 40 | 19 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 39 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 19 |
| Glipizide | Glipizide | 35 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 13 |
| Famotidine | Famotidine | 33 | 21 |
| Naproxen | Naproxen | 30 | 17 |
| Loperamide | Loperamide Hcl | 29 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Meloxicam | Meloxicam | 26 | 15 |
| Lidocaine | Lidocaine | 24 | suppressed |
| Ibu | Ibuprofen | 23 | 18 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 15 |
| Jardiance | Empagliflozin | 22 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | 11 |
| Eliquis | Apixaban | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 17 | 11 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Nystatin | Nystatin | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Tri-Estarylla | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $836.13 · 42 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPVAXIVE, COLLAGENASE SANTYL, COMIRNATY, ENFLONSIA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, JARDIANCE, KRYSTEXXA, Kerendia, M-M-R II, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PENMENVY, PREVNAR 20, QULIPTA, REPATHA, REXULTI, TRUMENBA, The Cologuard Plus Collection Kit, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error